HistoSonics Acquired by Investor Consortium

August 7, 2025—HistoSonics, the developer of the Edison histotripsy system and histotripsy therapy platform, announced a management-led majority stake acquisition by a syndicate of private and public investors, including K5 Global, Bezos Expeditions, Wellington Management, and other new and existing investors.

According to the company, the transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of the Edison system across new clinical indications and global markets.

HistoSonics stated it plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications, with a long-term vision of histotripsy being used across a wide range of clinical applications throughout the body, treating both benign and malignant conditions.

The company advised it will continue to be led by President and Chief Executive Officer, Mike Blue, and his executive team. Mr. Blue will also assume the role of Chairman of the Board upon closing.

“Our relentless focus as a company has been speed, scale, and the urgency to offer patients a better option than any they have today,” commented Blue in the company’s press release. “This new group of partners backs category-defining companies that transform entire industries. Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.”

As noted in the press release, HistoSonics was founded in 2009. It received FDA de novo clearance in October 2023 for its technology, which uses noninvasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a subcellular level and without the invasiveness or toxicity of traditional procedures.

The company is currently enrolling patients in clinical trials for liver tumors, kidney tumors (HOPE4KIDNEY trial), and pancreas tumors (GANNON trial) with plans to start others in the near future, stated HistoSonics.